1. Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; VL, viral load.
From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials
Clin Infect Dis. 2008;47(5): doi: /590943
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

2. Figure 2 Flow diagram of reviewed literature. PK, pharmacokinetic.
From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials
Clin Infect Dis. 2008;47(5): doi: /590943
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

3. Table 1 Characteristics of the study and intention-to-treat (ITT) populations.
From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials
Clin Infect Dis. 2008;47(5): doi: /590943
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

4. Table 2 Nucleoside reverse-transcriptase inhibitor (NRTI) backbone distribution and pooled resistance data at week 48 for ritonavir-boosted protease inhibitor (PI)- and non-NRTI (NNRTI)-based HAART regimens.
From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials
Clin Infect Dis. 2008;47(5): doi: /590943
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

5. Figure 3 Virologic failures in studies of nonnucleoside reverse-transcriptase inhibitor (NNRTI) and ritonavir-boosted protease inhibitor (bPI) HAART.
From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials
Clin Infect Dis. 2008;47(5): doi: /590943
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

6. Figure 4 Week 48 incidence of genotypic resistance at virologic failure. A, Intention-to-treat analysis. B, Genotype analysis. NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; TAM, thymidine analogue mutation.
From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials
Clin Infect Dis. 2008;47(5): doi: /590943
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

7. Figure 5 Week 96 incidence of genotypic resistance at virologic failure. A, Intention-to-treat analysis). B, Genotype analysis. NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; TAM, thymidine analogue mutation.
From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials
Clin Infect Dis. 2008;47(5): doi: /590943
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America